Breaking plastic-degradation technology could become a supplement that breaks microplastics in the gut before absorption
Predictor: Peter Diamandis · ep#245 "AI + Synthetic Biology: The Most Transformative Technology in Human History | Ben Lamm (Colossal)" · source
Prediction text
Breaking plastic-degradation technology could become a supplement that breaks microplastics in the gut before absorption | Imagine a supplement you could take that actually breaks down the bonds of the microplastics in your gut before it gets absorbed.
Verbatim quote
Imagine a supplement you could take that actually breaks down the bonds of the microplastics in your gut before it gets absorbed.
Predictor: Peter Diamandis
Calibration plot (stated vs observed)
Evidence about this node from Peter Diamandis is multiplied by κ in /api/intake. Lower κ = less weight; floors at 0.10 (effectively silenced) and caps at 1.00 (full weight).
Reference class
This node isn't linked to a reference class. The Bayesian update applies without outside-view blending.
Probability over time
Milestone chain
- 2026-02-12hitNovel PETase discovery via in-silico methods (bioRxiv preprint Feb 2026) advances thermostabilityHow: bioRxiv preprint confirms novel PETase variants with improved temperature/pH tolerance — a prerequisite for any oral / gut applicationSource: deep_research_enrichedconf 85%
- 2026-02-12hitEngineered PETase enzyme paper (Bhattacharya et al.) published in FEBS Journal — highly active polyester degradationHow: FEBS Journal publishes engineered PETase paper demonstrating substantial activity improvementSource: deep_research_enrichedconf 90%
- 2026-07-20pendingQ1 window check-in (25%)
- 2026-10-10pendingQ2 window check-in (50%)
- 2026-06-01 → 2027-06-30pendingPETase/MHETase variant with gut-compatible pH/temperature window (pH 1-7, 37C) demonstratedHow: Peer-reviewed paper demonstrates a plastic-degrading enzyme variant retaining substantial activity across human-GI conditions — critical gating step for any supplement formSource: deep_research_enrichedconf 40%
- 2026-12-31pendingQ3 window check-in (75%)
- 2026-09-01 → 2027-09-30pendingFirst published in-vivo (animal model) study of orally-delivered plastic-degrading enzyme on microplastic absorptionHow: Peer-reviewed animal study showing oral enzyme delivery reduces microplastic systemic uptake or fecal microplastic loadSource: deep_research_enrichedconf 25%
- 2027-01-01 → 2027-09-30pendingSupplement company / startup announces clinical work toward microplastic-degrading oral productHow: Public company / startup announcement of regulatory pathway (FDA pre-IND, NDIN, or equivalent) for oral plastic-degrading enzyme productSource: deep_research_enrichedconf 15%
What if this resolves?
Click a button to clamp this prediction and run a Gibbs sample. Returns the predictions whose marginals shift most. ~30s per run; ideal for stress-testing "if X resolves, what else moves?"
Evidence chain
Network propagation neighbors
Top incoming (parents)
Edges that influence THIS node's belief
| Kind | Node | Their prob | P(c|s=T) | P(c|s=F) | Δ implied |
|---|---|---|---|---|---|
| prereq | S_AGI_FAST_2027 AGI fast: drop-in remote worker by 2027-09 | 30.0% | 0.600 | 0.050 | -0.232 |
| killer | TK03 AI Regulatory Moratorium (EU/US Capability Freeze) | 10.0% | 0.050 | 0.600 | +0.098 |
| killer | TK01 AGI Capability Plateau (2026-27 Training Stall) | 15.0% | 0.050 | 0.600 | +0.071 |
| killer | TK14 Superbubble Pop (S&P 500 -40%, Moonshot Capital Evaporates) | 20.0% | 0.050 | 0.600 | +0.043 |
Top outgoing (children)
Predictions THIS node influences
No outgoing edges.
Ticker exposure
Beneficiaries (23)
Adverse (6)
Prerequisites (4)
| Type | Pred | Title | Domain | Lag |
|---|---|---|---|---|
| prereq | S_AGI_FAST_2027 | AGI fast: drop-in remote worker by 2027-09 | agi_general_capability | — |
| killer | TK14 | Superbubble Pop (S&P 500 -40%, Moonshot Capital Evaporates) | — | — |
| killer | TK01 | AGI Capability Plateau (2026-27 Training Stall) | — | — |
| killer | TK03 | AI Regulatory Moratorium (EU/US Capability Freeze) | — | — |
Dependents (0)
| Type | Pred | Title | Domain | Lag |
|---|---|---|---|---|
| No dependents | ||||
Linked documents (10)
| Sim | Source | Title | Market prob | Polarity | Reviewed | Published |
|---|---|---|---|---|---|---|
| 0.609 | fda | FDA NDA016730: DEXTROSE 5% IN PLASTIC CONTAINER (DEXTROSE) — B BRAUN | — | mentions | pending | 2026-05-12 |
| 0.597 | fda | FDA ANDA060469: TETRACYCLINE HYDROCHLORIDE (TETRACYCLINE HYDROCHLORIDE) — IMPAX LABS | — | mentions | pending | 2026-04-17 |
| 0.591 | fda | FDA NDA217186: CREXONT (CARBIDOPA) — IMPAX | — | mentions | pending | 2026-05-15 |
| 0.589 | fda | FDA ANDA210672: MULTIPLE VITAMINS INJECTION ADULT (ALPHA-TOCOPHEROL ACETATE) — APOTEX | — | mentions | pending | 2026-04-09 |
| 0.587 | fda | FDA ANDA210273: MULTIPLE VITAMINS INJECTION ADULT (ALPHA-TOCOPHEROL ACETATE) — APOTEX | — | mentions | pending | 2026-04-09 |
| 0.586 | fda | FDA ANDA090505: DOXYCYCLINE HYCLATE (DOXYCYCLINE HYCLATE) — IMPAX LABS INC | — | mentions | pending | 2026-04-09 |
| 0.584 | fda | FDA ANDA076521: CARBIDOPA AND LEVODOPA (CARBIDOPA) — IMPAX LABS | — | mentions | pending | 2026-05-28 |
| 0.582 | fda | FDA ANDA210671: MULTIPLE VITAMINS INJECTION PEDIATRIC (ASCORBIC ACID) — APOTEX | — | mentions | pending | 2026-04-21 |
| 0.581 | fda | FDA ANDA090431: DOXYCYCLINE HYCLATE (DOXYCYCLINE HYCLATE) — RISING | — | mentions | pending | 2026-04-09 |
| 0.580 | fda | FDA NDA018900: METRO I.V. IN PLASTIC CONTAINER (METRONIDAZOLE) — B BRAUN | — | mentions | pending | 2026-04-23 |
Raw metadata
{
"nia": false,
"url": "https://www.youtube.com/watch?v=Goa6c6Qz__I",
"mode": "SPECULATION",
"role": "Host",
"context": "Imagine a supplement you could take that actually breaks down the bonds of the microplastics in your gut before it gets absorbed.",
"verbatim": "Imagine a supplement you could take that actually breaks down the bonds of the microplastics in your gut before it gets absorbed.",
"conv_cues": "imagine",
"direction": "HAPPEN",
"timeframe": "Future",
"conv_level": "MEDIUM",
"milestones": [
{
"kind": "llm_pre_event",
"label": "Novel PETase discovery via in-silico methods (bioRxiv preprint Feb 2026) advances thermostability",
"source": "deep_research_enriched",
"status": "hit",
"weight": 0.4,
"ordinal": -7,
"source_id": null,
"confidence": 0.85,
"source_url": "https://www.biorxiv.org/content/10.64898/2026.02.12.705489v1.full",
"expected_date": "2026-02-12",
"observed_date": "2026-02-12",
"research_origin": "deep_research",
"measurement_criterion": "bioRxiv preprint confirms novel PETase variants with improved temperature/pH tolerance — a prerequisite for any oral / gut application"
},
{
"kind": "llm_pre_event",
"label": "Engineered PETase enzyme paper (Bhattacharya et al.) published in FEBS Journal — highly active polyester degradation",
"source": "deep_research_enriched",
"status": "hit",
"weight": 0.4,
"ordinal": -6,
"source_id": null,
"confidence": 0.9,
"source_url": "https://febs.onlinelibrary.wiley.com/doi/10.1111/febs.70228",
"expected_date": "2026-03-01",
"observed_date": "2026-02-12",
"research_origin": "deep_research",
"expected_date_range": {
"to": "2026-04-30",
"from": "2026-01-01"
},
"measurement_criterion": "FEBS Journal publishes engineered PETase paper demonstrating substantial activity improvement"
},
{
"kind": "quartile_checkpoint",
"label": "Q1 window check-in (25%)",
"status": "pending",
"weight": 0.05,
"ordinal": -5,
"source_id": null,
"expected_date": "2026-07-20",
"observed_date": null
},
{
"kind": "quartile_checkpoint",
"label": "Q2 window check-in (50%)",
"status": "pending",
"weight": 0.05,
"ordinal": -4,
"source_id": null,
"expected_date": "2026-10-10",
"observed_date": null
},
{
"kind": "llm_pre_event",
"label": "PETase/MHETase variant with gut-compatible pH/temperature window (pH 1-7, 37C) demonstrated",
"source": "deep_research_enriched",
"status": "pending",
"weight": 0.4,
"ordinal": -3,
"source_id": null,
"confidence": 0.4,
"source_url": "https://pubs.acs.org/doi/10.1021/acsenvironau.5c00033",
"expected_date": "2026-12-15",
"research_origin": "deep_research",
"expected_date_range": {
"to": "2027-06-30",
"from": "2026-06-01"
},
"measurement_criterion": "Peer-reviewed paper demonstrates a plastic-degrading enzyme variant retaining substantial activity across human-GI conditions — critical gating step for any supplement form"
},
{
"kind": "quartile_checkpoint",
"label": "Q3 window check-in (75%)",
"status": "pending",
"weight": 0.05,
"ordinal": -2,
"source_id": null,
"expected_date": "2026-12-31",
"observed_date": null
},
{
"kind": "llm_post_event",
"label": "First published in-vivo (animal model) study of orally-delivered plastic-degrading enzyme on microplastic absorption",
"source": "deep_research_enriched",
"status": "pending",
"weight": 0.4,
"ordinal": -1,
"source_id": null,
"confidence": 0.25,
"source_url": "https://pubs.rsc.org/en/content/articlelanding/2024/fd/d4fd00014e",
"expected_date": "2027-03-17",
"research_origin": "
... (truncated)